{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:14:23Z","timestamp":1793657663381,"version":"4.5.1"},"reference-count":219,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.pharmthera.2019.107426","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T12:23:54Z","timestamp":1571228634000},"page":"107426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":271,"special_numbering":"C","title":["The origin of NMDA receptor hypofunction in schizophrenia"],"prefix":"10.1016","volume":"205","author":[{"given":"Kazu","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Sapkota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2019.107426_bib0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/syn.1114","article-title":"NMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys","volume":"43","author":"Adams","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0010","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0006-8993(01)03115-8","article-title":"\u03b17-nicotinic receptor expression and the anatomical organization of hippocampal interneurons","volume":"922","author":"Adams","year":"2001","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0015","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0896-6273(90)90343-E","article-title":"Oxygen free radicals regulate NMDA receptor function via a redox modulatory site","volume":"5","author":"Aizenman","year":"1990","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0020","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0896-6273(89)90310-3","article-title":"Selective modulation of NMDA responses by reduction and oxidation","volume":"2","author":"Aizenman","year":"1989","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S2215-0366(19)30001-X","article-title":"The psychopathology of NMDAR-antibody encephalitis in adults: A systematic review and phenotypic analysis of individual patient data","volume":"6","author":"Al-Diwani","year":"2019","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0030","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00213-011-2539-2","article-title":"Acute elevations of brain kynurenic acid impair cognitive flexibility: Normalization by the \u03b17 positive modulator galantamine","volume":"220","author":"Alexander","year":"2012","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11064-018-2526-7","article-title":"In the telencephalon, GluN2C NMDA receptor subunit mRNA is predominately expressed in glial cells and GluN2D mRNA in interneurons","volume":"44","author":"Alsaad","year":"2019","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0040","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biopsych.2017.03.018","article-title":"Transcriptome alterations in prefrontal pyramidal cells distinguish schizophrenia from bipolar and major depressive disorders","volume":"82","author":"Arion","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0893-133X(01)00230-5","article-title":"Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release","volume":"25","author":"Balla","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0050","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10571-014-0027-z","article-title":"D-serine and serine racemase are localized to neurons in the adult mouse and human forebrain","volume":"34","author":"Balu","year":"2014","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0055","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/mp.2014.115","article-title":"Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia","volume":"20","author":"Banerjee","year":"2015","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0060","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/mp.2008.130","article-title":"Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior","volume":"14","author":"Basu","year":"2009","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0065","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1038\/ncomms7761","article-title":"Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system","volume":"6","author":"Baxter","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0070","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1152\/jn.00468.2018","article-title":"Colocalization of distinct NMDA receptor subtypes at excitatory synapses in the entorhinal cortex","volume":"121","author":"Beesley","year":"2019","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0075","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1126\/science.1148045","article-title":"Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase","volume":"318","author":"Behrens","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0080","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nn.2447","article-title":"Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes","volume":"13","author":"Belforte","year":"2010","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2006.10.010","article-title":"A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia","volume":"90","author":"Bendikov","year":"2007","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0090","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1176\/appi.ajp.2011.11030516","article-title":"Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study","volume":"168","author":"Benros","year":"2011","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0095","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF02450332","article-title":"Redox modulation of synaptic responses and plasticity in rat CA1 hippocampal neurons","volume":"113","author":"Bernard","year":"1997","journal-title":"Experimental Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-244X-9-71","article-title":"Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia","volume":"9","author":"Bitanihirwe","year":"2009","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1152\/jn.1997.77.1.309","article-title":"Trapping channel block of NMDA-activated responses by amantadine and memantine","volume":"77","author":"Blanpied","year":"1997","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.neuropharm.2017.02.024","article-title":"Kv3.1\/Kv3.2 channel positive modulators enable faster activating kinetics and increase firing frequency in fast-spiking GABAergic interneurons","volume":"118","author":"Boddum","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0115","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1523\/JNEUROSCI.5485-09.2010","article-title":"Intracellular redox state alters NMDA receptor response during aging through Ca2+\/calmodulin-dependent protein kinase II","volume":"30","author":"Bodhinathan","year":"2010","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresrev.2004.01.001","article-title":"Animal models of obstetric complications in relation to schizophrenia","volume":"45","author":"Boksa","year":"2004","journal-title":"Brain Research Brain Research Reviews"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pneurobio.2010.09.003","article-title":"The environment and susceptibility to schizophrenia","volume":"93","author":"Brown","year":"2011","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0130","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fnbeh.2018.00332","article-title":"Gene-environment interaction in a conditional NMDAR-knockout model of schizophrenia","volume":"12","author":"Bygrave","year":"2018","journal-title":"Frontiers in Behavioral Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0135","article-title":"Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation","author":"Cai","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0140","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.nbd.2017.10.006","article-title":"A lack of GluN2A-containing NMDA receptors confers a vulnerability to redox dysregulation: Consequences on parvalbumin interneurons, and their perineuronal nets","volume":"109","author":"Cardis","year":"2018","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0145","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/mp.2011.31","article-title":"A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior","volume":"17","author":"Carlen","year":"2012","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.biopsycho.2015.10.013","article-title":"A quantitative review of the postmortem evidence for decreased cortical N-methyl-d-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity deficits?","volume":"116","author":"Catts","year":"2016","journal-title":"Biological Psychology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0155","doi-asserted-by":"crossref","first-page":"17496","DOI":"10.1038\/s41598-017-17406-x","article-title":"Pharmacological modulation of Kv3.1 mitigates auditory midbrain temporal processing deficits following auditory nerve damage","volume":"7","author":"Chambers","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.schres.2017.03.012","article-title":"Seroprevalence survey of selective anti-neuronal autoantibodies in patients with first-episode schizophrenia and chronic schizophrenia","volume":"190","author":"Chen","year":"2017","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0165","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1471-4159.2006.03991.x","article-title":"The chemical biology of clinically tolerated NMDA receptor antagonists","volume":"97","author":"Chen","year":"2006","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0170","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/schbul\/sbl033","article-title":"Elevations of endogenous kynurenic acid produce spatial working memory deficits","volume":"33","author":"Chess","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41467-017-00218-y","article-title":"Afferent specific role of NMDA receptors for the circuit integration of hippocampal neurogliaform cells","volume":"8","author":"Chittajallu","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0180","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.schres.2014.12.026","article-title":"The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia","volume":"167","author":"Cohen","year":"2015","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0185","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/clpt.1982.87","article-title":"Phencyclidine disposition after intravenous and oral doses","volume":"31","author":"Cook","year":"1982","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0190","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","article-title":"Glutamate and schizophrenia: Beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0195","first-page":"35","article-title":"The role of serine racemase in the pathophysiology of brain disorders","volume":"82","author":"Coyle","year":"2018","journal-title":"Advances in Pharmacology (San Diego, Calif)"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0200","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1196\/annals.1300.020","article-title":"Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia","volume":"1003","author":"Coyle","year":"2003","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0205","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0210","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0215","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.conb.2009.05.001","article-title":"Redox dysregulation, neurodevelopment, and schizophrenia","volume":"19","author":"Do","year":"2009","journal-title":"Current Opinion in Neurobiology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0220","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mp.2016.121","article-title":"Stem cell-derived interneuron transplants as a treatment for schizophrenia: Preclinical validation in a rodent model","volume":"22","author":"Donegan","year":"2017","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0225","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fnsyn.2016.00020","article-title":"The emergence of NMDA receptor metabotropic function: Insights from imaging","volume":"8","author":"Dore","year":"2016","journal-title":"Frontiers in Synaptic Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0230","first-page":"3346","article-title":"Scavenging ROS dramatically increase NMDA receptor whole-cell currents in painted turtle cortical neurons","volume":"217","author":"Dukoff","year":"2014","journal-title":"The Journal of Experimental Biology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0235","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/embj.201386356","article-title":"Surface dynamics of GluN2B-NMDA receptors controls plasticity of maturing glutamate synapses","volume":"33","author":"Dupuis","year":"2014","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0240","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tins.2015.06.002","article-title":"Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment","volume":"38","author":"Ellaithy","year":"2015","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0245","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2015.00476","article-title":"Immunological findings in psychotic syndromes: A tertiary care hospital\u2019s CSF sample of 180 patients","volume":"9","author":"Endres","year":"2015","journal-title":"Frontiers in Human Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0250","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-201X.2002.00962.x","article-title":"Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid","volume":"175","author":"Erhardt","year":"2002","journal-title":"Acta Physiologica Scandinavica"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0255","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2004.06.006","article-title":"Endogenous kynurenic acid disrupts prepulse inhibition","volume":"56","author":"Erhardt","year":"2004","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0260","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuropharm.2016.05.020","article-title":"The kynurenine pathway in schizophrenia and bipolar disorder","volume":"112","author":"Erhardt","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0265","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41592-018-0142-8","article-title":"All-optical synaptic electrophysiology probes mechanism of ketamine-induced disinhibition","volume":"15","author":"Fan","year":"2018","journal-title":"Nature Methods"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0270","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/nature08928","article-title":"Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling","volume":"464","author":"Fazzari","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0275","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1601-183X.2005.00176.x","article-title":"Performance deficit of \u03b17 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working\/episodic-like memory","volume":"5","author":"Fernandes","year":"2006","journal-title":"Genes, Brain, and Behavior"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0280","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1523\/JNEUROSCI.0932-17.2017","article-title":"Preferential disruption of prefrontal GABAergic function by nanomolar concentrations of the \u03b17nACh negative modulator kynurenic acid","volume":"37","author":"Flores-Barrera","year":"2017","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0285","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/schbul\/sby125","article-title":"Oxidative stress and inflammation in first-episode psychosis: A systematic review and meta-analysis","volume":"45","author":"Fraguas","year":"2019","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0290","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1038\/s41467-017-02172-1","article-title":"Input-dependent regulation of excitability controls dendritic maturation in somatosensory thalamocortical neurons","volume":"8","author":"Frangeul","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0295","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1111\/ejn.13626","article-title":"A small molecule activator of Nav 1.1 channels increases fast-spiking interneuron excitability and GABAergic transmission in vitro and has anti-convulsive effects in vivo","volume":"46","author":"Frederiksen","year":"2017","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0300","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.schres.2018.07.019","article-title":"Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis","volume":"202","author":"Gallego","year":"2018","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0305","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/nn.4402","article-title":"Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia","volume":"19","author":"Genovese","year":"2016","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0310","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.neuropsych.17120343","article-title":"The psychiatric phenotype of Anti-NMDA receptor encephalitis","volume":"31","author":"Gibson","year":"2019","journal-title":"The Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0315","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1523\/JNEUROSCI.0064-12.2012","article-title":"Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain","volume":"32","author":"Gleichman","year":"2012","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0320","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0325","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.biopsych.2015.11.007","article-title":"Dopamine system dysregulation and the pathophysiology of schizophrenia: Insights from the methylazoxymethanol acetate model","volume":"81","author":"Grace","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0330","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1017\/S1461145708009085","article-title":"Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: Association with N-methyl-d-aspartic acid receptor up-regulation","volume":"12","author":"Gray","year":"2009","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0335","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neulet.2018.01.024","article-title":"Genetic deletion of NMDA receptors suppresses GABAergic synaptic transmission in two distinct types of central neurons","volume":"668","author":"Gu","year":"2018","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0340","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jnc.14101","article-title":"Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in the MAM model for schizophrenia","volume":"143","author":"Gulchina","year":"2017","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062438","article-title":"Neonatal disruption of serine racemase causes schizophrenia-like behavioral abnormalities in adulthood: Clinical rescue by D-Serine","volume":"8","author":"Hagiwara","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0350","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nm1418","article-title":"Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia","volume":"12","author":"Hahn","year":"2006","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0355","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1476-5381.1989.tb11841.x","article-title":"The mechanism of action and pharmacological specificity of the anticonvulsant NMDA antagonist MK-801: A voltage clamp study on neuronal cells in culture","volume":"96","author":"Halliwell","year":"1989","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0360","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1085\/jgp.201812032","article-title":"Structure, function, and allosteric modulation of NMDA receptors","volume":"150","author":"Hansen","year":"2018","journal-title":"The Journal of General Physiology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0365","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1523\/JNEUROSCI.1392-18.2019","article-title":"Tonic activation of GluN2C\/GluN2D-containing NMDA receptors by ambient glutamate facilitates cortical interneuron maturation","volume":"39","author":"Hanson","year":"2019","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0370","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrn.2015.19","article-title":"Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis","volume":"17","author":"Hardingham","year":"2016","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0375","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0269881114553647","article-title":"Recent genetic findings in schizophrenia and their therapeutic relevance","volume":"29","author":"Harrison","year":"2015","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0380","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.biopsych.2005.11.002","article-title":"Neuregulin 1 and schizophrenia: Genetics, gene expression, and neurobiology","volume":"60","author":"Harrison","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0385","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archpsyc.60.6.572","article-title":"Decreased serum levels of d-serine in patients with schizophrenia: Evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia","volume":"60","author":"Hashimoto","year":"2003","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0390","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.mp.4001434","article-title":"Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia","volume":"9","author":"Hashimoto","year":"2004","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0395","first-page":"591S","article-title":"D-CPPene (SDZ EAA 494), a competitive NMDA antagonist. Results from animal models and first results in humans","volume":"10","author":"Herrling","year":"1994","journal-title":"Neuropsychopharmacplogy"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0400","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0304-3940(94)91051-0","article-title":"Hypoxia-induced modification of the N-methyl-d-aspartate receptor in the brain of the newborn piglet","volume":"167","author":"Hoffman","year":"1994","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0405","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev.ne.17.030194.000335","article-title":"Cloned glutamate receptors","volume":"17","author":"Hollmann","year":"1994","journal-title":"Annual Review of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0410","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0415","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fncel.2017.00353","article-title":"NMDA receptors regulate the development of neuronal intrinsic excitability through cell-autonomous mechanisms","volume":"11","author":"Hou","year":"2017","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0420","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: Version III--The final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0425","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jphs.2016.10.002","article-title":"Human GRIN2B variants in neurodevelopmental disorders","volume":"132","author":"Hu","year":"2016","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0430","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.12547","article-title":"The glutamate hypothesis of schizophrenia: Evidence from human brain tissue studies","volume":"1338","author":"Hu","year":"2015","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0435","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1073\/pnas.85.4.1307","article-title":"Block of N-methyl-d-aspartate-activated current by the anticonvulsant MK-801: Selective binding to open channels","volume":"85","author":"Huettner","year":"1988","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0440","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0445","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nbd.2012.11.013","article-title":"Losing your inhibition: Linking cortical GABAergic interneurons to schizophrenia","volume":"53","author":"Inan","year":"2013","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0450","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2202-14-17","article-title":"In vitro neuronal network activity in NMDA receptor encephalitis","volume":"14","author":"Jantzen","year":"2013","journal-title":"BMC Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0455","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0460","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1126\/science.277.5328.953","article-title":"Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine","volume":"277","author":"Jentsch","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0465","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0893-133X(98)00004-9","article-title":"Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion","volume":"19","author":"Jentsch","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0470","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.tins.2018.05.002","article-title":"Pathogenicity of antibodies against NMDA receptor: Molecular insights into autoimmune psychosis","volume":"41","author":"Jezequel","year":"2018","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0475","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.biopsych.2012.12.004","article-title":"Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons","volume":"73","author":"Jiang","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0480","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.coph.2014.11.006","article-title":"Recent insights into the mode of action of memantine and ketamine","volume":"20","author":"Johnson","year":"2015","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0485","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0304-3940(93)90341-H","article-title":"Basket-like interneurones in layer II of the entorhinal cortex exhibit a powerful NMDA-mediated synaptic excitation","volume":"149","author":"Jones","year":"1993","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0490","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/abbs\/gmv135","article-title":"The involvement of N-methyl-d-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia","volume":"48","author":"Ju","year":"2016","journal-title":"Acta Biochimica et Biophysica Sinica"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0495","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/jcbfm.2014.104","article-title":"Highly energized inhibitory interneurons are a central element for information processing in cortical networks","volume":"34","author":"Kann","year":"2014","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0500","doi-asserted-by":"crossref","first-page":"e1186","DOI":"10.1038\/tp.2017.162","article-title":"Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia","volume":"7","author":"Kannan","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0505","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.brainresbull.2010.04.006","article-title":"N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?","volume":"83","author":"Kantrowitz","year":"2010","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0510","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biopsych.2010.09.012","article-title":"Reduced dysbindin expression mediates N-methyl-d-aspartate receptor hypofunction and impaired working memory performance","volume":"69","author":"Karlsgodt","year":"2011","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0515","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/mp.2016.69","article-title":"Exome sequencing for bipolar disorder points to roles of de novo loss-of-function and protein-altering mutations","volume":"21","author":"Kataoka","year":"2016","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0520","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0006-3223(00)00976-8","article-title":"Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia","volume":"48","author":"Kegeles","year":"2000","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0525","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0022-3565(25)24082-4","article-title":"MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys","volume":"245","author":"Koek","year":"1988","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0530","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/mp.2017.190","article-title":"The effects of ketamine on dopaminergic function: Meta-analysis and review of the implications for neuropsychiatric disorders","volume":"23","author":"Kokkinou","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0535","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0006-3223(96)00047-9","article-title":"Psychotogenicity and N-methyl-d-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy","volume":"41","author":"Kornhuber","year":"1997","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0540","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.neuron.2010.09.017","article-title":"NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory","volume":"68","author":"Korotkova","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0545","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0418-17.2018","article-title":"Neuregulin 1 type I overexpression is associated with reduced NMDA receptor-mediated synaptic signaling in hippocampal interneurons expressing PV or CCK","volume":"5","author":"Kotzadimitriou","year":"2018","journal-title":"eNeuro"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0550","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/oxim.3.1.10028","article-title":"Clinical physiology and mechanism of dizocilpine (MK-801): Electron transfer, radicals, redox metabolites and bioactivity","volume":"3","author":"Kovacic","year":"2010","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0555","doi-asserted-by":"crossref","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans","volume":"51","author":"Krystal","year":"1994","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0560","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/hmg\/ddp261","article-title":"Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model","volume":"18","author":"Labrie","year":"2009","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0565","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1016\/j.celrep.2018.05.096","article-title":"NMDA receptor autoantibodies in autoimmune encephalitis cause a subunit-specific nanoscale redistribution of NMDA receptors","volume":"23","author":"Ladepeche","year":"2018","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0570","doi-asserted-by":"crossref","first-page":"14291","DOI":"10.1074\/jbc.M114.553750","article-title":"Mutations in the BLOC-1 subunits dysbindin and muted generate divergent and dosage-dependent phenotypes","volume":"289","author":"Larimore","year":"2014","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0575","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1073\/pnas.0602002103","article-title":"Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5\u2032 SNPs associated with the disease","volume":"103","author":"Law","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0580","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1212\/WNL.0000000000002740","article-title":"Delineating the GRIN1 phenotypic spectrum: A distinct genetic NMDA receptor encephalopathy","volume":"86","author":"Lemke","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0585","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2215-0366(16)30375-3","article-title":"Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: A case-control study","volume":"4","author":"Lennox","year":"2017","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0590","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1212\/WNL.0b013e3182a9f531","article-title":"Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: Case report","volume":"81","author":"Leypoldt","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0595","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3389\/fphar.2019.00540","article-title":"The role of N-methyl-d-aspartate receptor neurotransmission and precision medicine in behavioral and psychological symptoms of dementia","volume":"10","author":"Lin","year":"2019","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0600","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.mcn.2014.06.007","article-title":"Cortical parvalbumin GABAergic deficits with \u03b17 nicotinic acetylcholine receptor deletion: Implications for schizophrenia","volume":"61","author":"Lin","year":"2014","journal-title":"Molecular and Cellular Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0605","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fncel.2016.00034","article-title":"D-Serine and serine racemase are associated with PSD-95 and glutamatergic synapse stability","volume":"10","author":"Lin","year":"2016","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0610","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuropharm.2015.10.028","article-title":"Inhibition of kynurenine aminotransferase II reduces activity of midbrain dopamine neurons","volume":"102","author":"Linderholm","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0615","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0166-2236(02)02245-2","article-title":"Cysteine regulation of protein function--as exemplified by NMDA-receptor modulation","volume":"25","author":"Lipton","year":"2002","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0620","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tins.2008.02.005","article-title":"Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia","volume":"31","author":"Lisman","year":"2008","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0625","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnins.2019.00043","article-title":"The role of NMDA receptors in Alzheimer\u2019s disease","volume":"13","author":"Liu","year":"2019","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0630","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1111\/bph.13222","article-title":"Ketamine and phencyclidine: The good, the bad and the unexpected","volume":"172","author":"Lodge","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0635","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0022-3565(25)22942-1","article-title":"Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine","volume":"256","author":"L\u00f6scher","year":"1991","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0640","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/gim.2014.83","article-title":"Delineating the 15q13.3 microdeletion phenotype: A case series and comprehensive review of the literature","volume":"17","author":"Lowther","year":"2015","journal-title":"Genetics in Medicine"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0645","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2017.00037","article-title":"From toxoplasmosis to schizophrenia via NMDA dysfunction: Peptide overlap between toxoplasma gondii and N-methyl-d-aspartate receptors as a potential mechanistic link","volume":"8","author":"Lucchese","year":"2017","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0650","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1215040","article-title":"A systematic survey of loss-of-function variants in human protein-coding genes","volume":"335","author":"MacArthur","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0655","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.schres.2017.04.027","article-title":"Anti-neuronal anti-bodies in patients with early psychosis","volume":"192","author":"Mantere","year":"2018","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0660","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.neuro.23.1.649","article-title":"Synaptic plasticity and memory: An evaluation of the hypothesis","volume":"23","author":"Martin","year":"2000","journal-title":"Annual Review of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0665","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tins.2016.02.006","article-title":"NMDA receptor internalization by autoantibodies: A reversible mechanism underlying psychosis?","volume":"39","author":"Masdeu","year":"2016","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0670","first-page":"619","article-title":"Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia","volume":"11","author":"Masopust","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0675","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuron.2014.06.007","article-title":"Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases","volume":"83","author":"Mei","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0680","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/brain\/aws092","article-title":"Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis","volume":"135","author":"Mikasova","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0685","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0361-9230(95)02144-2","article-title":"Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats","volume":"40","author":"Miller","year":"1996","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0690","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/BF00968404","article-title":"Modification of modulatory sites of NMDA receptor in the fetal guinea pig brain during development","volume":"17","author":"Mishra","year":"1992","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0695","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.tins.2014.12.005","article-title":"Translating the MAM model of psychosis to humans","volume":"38","author":"Modinos","year":"2015","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0700","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.3390\/ijms19123800","article-title":"Flux-independent NMDAR signaling: Molecular mediators, cellular functions, and complexities","volume":"19","author":"Montes de Oca Balderas","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0705","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuropharm.2013.03.004","article-title":"NMDA receptor-dependent function and plasticity in inhibitory circuits","volume":"74","author":"Moreau","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0710","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.24195","article-title":"Acute mechanisms underlying antibody effects in anti-N-methyl-d-aspartate receptor encephalitis","volume":"76","author":"Moscato","year":"2014","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0715","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neubiorev.2016.06.001","article-title":"Neuregulin-1 and schizophrenia in the genome-wide association study era","volume":"68","author":"Mostaid","year":"2016","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0720","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fnins.2015.00372","article-title":"The role of inflammation in schizophrenia","volume":"9","author":"Muller","year":"2015","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0725","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.neuroscience.2013.08.024","article-title":"Localization of \u03b17 nicotinic acetylcholine receptor immunoreactivity on GABAergic interneurons in layers I-III of the rat retrosplenial granular cortex","volume":"252","author":"Murakami","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0730","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.schres.2017.12.007","article-title":"Is the prevalence of anti-N-methyl-d-aspartate receptor antibodies in schizophrenia overestimated?","volume":"197","author":"Nakagami","year":"2018","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0735","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/schbul\/sby003","article-title":"Schizophrenia-like dopamine release abnormalities in a mouse model of NMDA receptor hypofunction","volume":"45","author":"Nakao","year":"2019","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0740","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fnins.2014.00168","article-title":"Brain state-dependent abnormal LFP activity in the auditory cortex of a schizophrenia mouse model","volume":"8","author":"Nakao","year":"2014","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0745","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41537-016-0003-3","article-title":"Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia","volume":"3","author":"Nakazawa","year":"2017","journal-title":"NPJ Schizophrenia"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0750","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrn1385","article-title":"NMDA receptors, place cells and hippocampal spatial memory","volume":"5","author":"Nakazawa","year":"2004","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0755","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.neuropharm.2011.01.022","article-title":"GABAergic interneuron origin of schizophrenia pathophysiology","volume":"62","author":"Nakazawa","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0760","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.178","article-title":"Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry","volume":"7","author":"Nucifora","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0765","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0306-4522(03)00157-X","article-title":"Large variability in synaptic N-methyl-d-aspartate receptor density on interneurons and a comparison with pyramidal-cell spines in the rat hippocampus","volume":"119","author":"Nyiri","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0770","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.bbr.2018.03.026","article-title":"Schizophrenia-relevant behaviours of female mice overexpressing neuregulin 1 type III","volume":"353","author":"Olaya","year":"2018","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0775","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/schbul\/sbx122","article-title":"Overexpression of neuregulin 1 type III confers hippocampal mRNA alterations and schizophrenia-like behaviors in mice","volume":"44","author":"Olaya","year":"2018","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0780","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0785","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41380-018-0220-4","article-title":"Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: A systematic review and meta-analysis","volume":"24","author":"Orlovska-Waast","year":"2019","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0790","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41380-017-0011-3","article-title":"Uncoupling the widespread occurrence of anti-NMDAR1 autoantibodies from neuropsychiatric disease in a novel autoimmune model","volume":"24","author":"Pan","year":"2019","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0795","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nn2071","article-title":"Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses","volume":"11","author":"Papadia","year":"2008","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0800","doi-asserted-by":"crossref","first-page":"16865","DOI":"10.1523\/JNEUROSCI.2449-13.2013","article-title":"The infralimbic cortex bidirectionally modulates mesolimbic dopamine neuron activity via distinct neural pathways","volume":"33","author":"Patton","year":"2013","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0805","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/cercor\/bhg132","article-title":"Parvalbumin expression in visual cortical interneurons depends on neuronal activity and TrkB ligands during an Early period of postnatal development","volume":"14","author":"Patz","year":"2004","journal-title":"Cerebral Cortex"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0810","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.schres.2014.05.001","article-title":"Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder","volume":"157","author":"Pearlman","year":"2014","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0815","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41380-018-0341-9","article-title":"NMDA 2A receptors in parvalbumin cells mediate sex-specific rapid ketamine response on cortical activity","volume":"24","author":"Picard","year":"2019","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0820","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nm.2315","article-title":"Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors","volume":"17","author":"Pitcher","year":"2011","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0825","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/schbul\/sbw221","article-title":"Kynurenic acid in schizophrenia: A systematic review and meta-analysis","volume":"43","author":"Plitman","year":"2017","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0830","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/ejn.12489","article-title":"The synapse in schizophrenia","volume":"39","author":"Pocklington","year":"2014","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0835","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1017\/S003329171300295X","article-title":"Prevalence of anti-N-methyl-d-aspartate (NMDA) receptor antibodies in patients with schizophrenia and related psychoses: A systematic review and meta-analysis","volume":"44","author":"Pollak","year":"2014","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0840","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/ejn.13128","article-title":"Tonically active NMDA receptors--a signalling mechanism critical for interneuronal excitability in the CA1 stratum radiatum","volume":"43","author":"Riebe","year":"2016","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0845","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neuron.2006.09.015","article-title":"Neurobiology of schizophrenia","volume":"52","author":"Ross","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0850","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1469-7610.2009.02187.x","article-title":"Research review: Cholinergic mechanisms, early brain development, and risk for schizophrenia","volume":"51","author":"Ross","year":"2010","journal-title":"Journal of Child Psychology and Psychiatry, and Allied Disciplines"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0855","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1212\/NXI.0000000000000458","article-title":"Anti-NMDA receptor encephalitis and nonencephalitic HSV-1 infection","volume":"5","author":"Salovin","year":"2018","journal-title":"NeurologyNeuroimmunology & Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0860","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1124\/jpet.115.230391","article-title":"GluN2D N-methyl-d-aspartate receptor subunit contribution to the stimulation of brain activity and gamma oscillations by ketamine: Implications for schizophrenia","volume":"356","author":"Sapkota","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0865","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00702-006-0440-7","article-title":"Altered NMDA receptor expression and behavior following postnatal hypoxia: Potential relevance to schizophrenia","volume":"114","author":"Schmitt","year":"2007","journal-title":"Journal of neural transmission (Vienna, Austria: 1996)"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0870","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrn3257","article-title":"Kynurenines in the mammalian brain: When physiology meets pathology","volume":"13","author":"Schwarcz","year":"2012","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0875","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1503\/jpn.140126","article-title":"Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway","volume":"40","author":"Schwieler","year":"2015","journal-title":"Journal of Psychiatry & Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0880","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/mp.2015.186","article-title":"A genome-wide association study of kynurenic acid in cerebrospinal fluid: Implications for psychosis and cognitive impairment in bipolar disorder","volume":"21","author":"Sellgren","year":"2016","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2013.04.001","article-title":"Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species","volume":"106\u2013107","author":"Semple","year":"2013","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0890","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/acn3.592","article-title":"Monoclonal antibodies from a patient with anti-NMDA receptor encephalitis","volume":"5","author":"Sharma","year":"2018","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0895","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.1038\/s41598-019-43957-2","article-title":"Differential effect of NMDA receptor GluN2C and GluN2D subunit ablation on behavior and channel blocker-induced schizophrenia phenotypes","volume":"9","author":"Shelkar","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0900","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","article-title":"Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study","volume":"72","author":"Slifstein","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0905","article-title":"NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms","author":"Snyder","year":"2019","journal-title":"Schizophrenia Research"},{"issue":"Pt 3","key":"10.1016\/j.pharmthera.2019.107426_bib0910","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1469-7793.2000.t01-2-00493.x","article-title":"The trapping block of NMDA receptor channels in acutely isolated rat hippocampal neurones","volume":"526","author":"Sobolevsky","year":"2000","journal-title":"Journal de Physiologie"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0915","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1212\/WNL.0000000000005614","article-title":"Encephalitis with mGluR5 antibodies: Symptoms and antibody effects","volume":"90","author":"Spatola","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0920","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.neuroscience.2005.10.014","article-title":"Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia","volume":"137","author":"Steullet","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0925","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/brain\/awy304","article-title":"GRIN2A-related disorders: Genotype and functional consequence predict phenotype","volume":"142","author":"Strehlow","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0930","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bph.12518","article-title":"GluN2C\/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice","volume":"171","author":"Suryavanshi","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0935","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neuron.2006.11.023","article-title":"Hypoxia enhances S-nitrosylation-mediated NMDA receptor inhibition via a thiol oxygen sensor motif","volume":"53","author":"Takahashi","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0940","doi-asserted-by":"crossref","first-page":"14116","DOI":"10.1523\/JNEUROSCI.2786-11.2011","article-title":"GABAergic precursor transplantation into the prefrontal cortex prevents phencyclidine-induced cognitive deficits","volume":"31","author":"Tanaka","year":"2011","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0945","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamapsychiatry.2016.2619","article-title":"The 40-Hz auditory steady-state response in patients with schizophrenia: A meta-analysis","volume":"73","author":"Thune","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0950","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1074\/jbc.272.8.5157","article-title":"Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-d-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies","volume":"272","author":"Tingley","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0955","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bbi.2019.06.017","article-title":"Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia","volume":"81","author":"Tong","year":"2019","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0960","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/schbul\/sbl050","article-title":"Antibodies to Toxoplasma gondii in patients with schizophrenia: A meta-analysis","volume":"33","author":"Torrey","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0965","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.schres.2011.08.014","article-title":"Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats","volume":"133","author":"Trecartin","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0970","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0014-2999(89)90754-1","article-title":"The behavioural effects of MK-801: A comparison with antagonists acting non-competitively and competitively at the NMDA receptor","volume":"167","author":"Tricklebank","year":"1989","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0975","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-244X-12-37","article-title":"Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features","volume":"12","author":"Tsutsui","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0980","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neuropharm.2018.06.003","article-title":"Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia","volume":"138","author":"Tufvesson-Alm","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0985","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neubiorev.2018.11.012","article-title":"Toxoplasmosis: A pathway to neuropsychiatric disorders","volume":"96","author":"Tyebji","year":"2019","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0990","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/aji.12282","article-title":"IL-1beta increases expression of tryptophan 2,3-dioxygenase and stimulates tryptophan catabolism in endometrioma stromal cells","volume":"72","author":"Urata","year":"2014","journal-title":"American Journal of Reproductive Immunology (New York, NY: 1989)"},{"key":"10.1016\/j.pharmthera.2019.107426_bib0995","first-page":"95","article-title":"GluN2D-containing NMDA receptors-mediate synaptic currents in hippocampal interneurons and pyramidal cells in juvenile mice","volume":"9","author":"von Engelhardt","year":"2015","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1000","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1038\/ncomms8222","article-title":"A negative feedback loop controls NMDA receptor function in cortical interneurons via neuregulin 2\/ErbB4 signalling","volume":"6","author":"Vullhorst","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1005","doi-asserted-by":"crossref","first-page":"12255","DOI":"10.1523\/JNEUROSCI.2454-09.2009","article-title":"Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus","volume":"29","author":"Vullhorst","year":"2009","journal-title":"The Journal of Neuroscience"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2019.107426_bib1010","first-page":"S191","article-title":"Structure, function, and pharmacology of NMDA receptor channels","volume":"63","author":"Vyklicky","year":"2014","journal-title":"Physiological research\/Academia Scientiarum Bohemoslovaca"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/schbul\/sbx035","article-title":"Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder, and depression","volume":"44","author":"Wang","year":"2018","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1020","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.neuropharm.2011.11.024","article-title":"Prolonged exposure to NMDAR antagonist induces cell-type specific changes of glutamatergic receptors in rat prefrontal cortex","volume":"62","author":"Wang","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1025","doi-asserted-by":"crossref","first-page":"eaat5691","DOI":"10.1126\/science.aat5691","article-title":"Three-dimensional intact-tissue sequencing of single-cell transcriptional states","volume":"361","author":"Wang","year":"2018","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000077523","article-title":"NMDA receptors in the developing brain and effects of noxious insults","volume":"13","author":"Waters","year":"2004","journal-title":"Neuro-Signals"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biopsych.2016.03.2104","article-title":"Pathway-specific dopamine abnormalities in schizophrenia","volume":"81","author":"Weinstein","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nature11208","article-title":"Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function","volume":"486","author":"Won","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1045","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archpsyc.61.7.649","article-title":"Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-d-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder","volume":"61","author":"Woo","year":"2004","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2015.12.027","article-title":"Stereotactic injection of cerebrospinal fluid from anti-NMDA receptor encephalitis into rat dentate gyrus impairs NMDA receptor function","volume":"1633","author":"Wurdemann","year":"2016","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1055","doi-asserted-by":"crossref","first-page":"11246","DOI":"10.1523\/JNEUROSCI.2488-10.2010","article-title":"Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses","volume":"30","author":"Xia","year":"2010","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cophys.2017.12.013","article-title":"De novo mutations and rare variants occurring in NMDA receptors","volume":"2","author":"XiangWei","year":"2018","journal-title":"Current Opinion in Physiology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1065","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neulet.2015.10.049","article-title":"Role of the NMDA receptor GluN2D subunit in the expression of ketamine-induced behavioral sensitization and region-specific activation of neuronal nitric oxide synthase","volume":"610","author":"Yamamoto","year":"2016","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1070","first-page":"28","article-title":"Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients","volume":"21","author":"Yenari","year":"1998","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41398-017-0061-y","article-title":"Rare loss of function mutations in N-methyl-d-aspartate glutamate receptors and their contributions to schizophrenia susceptibility","volume":"8","author":"Yu","year":"2018","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1080","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00415-010-5788-9","article-title":"Disease-relevant autoantibodies in first episode schizophrenia","volume":"258","author":"Zandi","year":"2011","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1085","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.nbd.2011.09.019","article-title":"Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients","volume":"45","author":"Zhang","year":"2012","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1090","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1111\/bph.12758","article-title":"Allosteric modulation of GluN2C\/GluN2D-containing NMDA receptors bidirectionally modulates dopamine release: Implication for Parkinson\u2019s disease","volume":"171","author":"Zhang","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107426_bib1095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2013.03.030","article-title":"NMDA receptors in nervous system diseases","volume":"74","author":"Zhou","year":"2013","journal-title":"Neuropharmacology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:02:43Z","timestamp":1759010563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725819301780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":219,"alternative-id":["S0163725819301780"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107426","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The origin of NMDA receptor hypofunction in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107426"}}